Silexion Therapeutics Corp SEC filings SLXNW

Silexion Therapeutics Corp has 279 filings in SEC EDGAR's recent list, going back to May 9, 2024. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (bylaw or fiscal year change, shareholder vote results). The company's fiscal year ends on December 31.

Silexion Therapeutics Corp SEC filings
Form Description Filed Period
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
10-Q Quarterly report May 15, 2026 Mar 31, 2026
10-Q Quarterly report Nov 12, 2025 Sep 30, 2025
10-Q Quarterly report Aug 12, 2025 Jun 30, 2025
10-Q Quarterly report May 13, 2025 Mar 31, 2025
10-Q Quarterly report Nov 14, 2024 Sep 30, 2024
10-Q Quarterly report Aug 29, 2024 Jun 30, 2024

Showing 7 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
SLXN (Nasdaq), SLXNW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Ramat Gan, Israel
SEC filer status
, Emerging growth company
SEC CIK
2022416
Former names
Biomotion Sciences (until Aug 15, 2024)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.